<p>David Moss from Lipoxen plc in the United Kingdom aims to develop a non-live polio vaccine using liposomes to entrap and deliver defined poliovirus antigens effectively to the immune system. If successful, the project will expedite the development and global deployment of a simple, economic new polio vaccine.</p>


David Moss from Lipoxen plc in the United Kingdom aims to develop a non-live polio vaccine using liposomes to entrap and deliver defined poliovirus antigens effectively to the immune system. If successful, the project will expedite the development and global deployment of a simple, economic new polio vaccine.

Development of a Non-live Liposomal Polio Vaccine

Great ideas come from everywhere.

Sign up for email updates of the latest grant opportunities and awards.

View the Grand Challenges partnership network

.css-1nxq281{overflow:hidden;display:inline-block;}.css-1nxq281 span{display:inline-block;}Great ideas come from everywhere.

Sign up for email updates of the latest grant opportunities and awards.

View the Grand Challenges partnership network

Great ideas come from everywhere.